Stevenage, UK, September 6th 2016 – Stevenage Bioscience Catalyst (SBC), the open innovation campus driving collaboration to improve healthcare, is pleased to announce that Dave Allen of GSK and Daniel Nelki of Wellcome have joined its Board. As representatives of major stakeholders and experts in innovation, they will help drive the evolution of the campus into its next phase of development. They replace Ian Tomlinson, now independent Chairman of the SBC Board, and John Cooper, who retired recently, respectively.
Dave Allen is the head of the Respiratory Therapy Area at GSK, responsible for the identification of novel medicines and their progression to global registration. He leads a group of over 200 scientists and clinicians addressing major unmet needs in this therapeutic area and is GSK’s Chief Chemist. Dave joined the company as are search chemist after completing his studies, and has also worked on antibiotics and cardiovascular medicines.
Daniel Nelki is the Science to Health lead and part of the Management Team of the Innovations Division at Wellcome, supporting its translational activities. Prior to joining the charity, he was a post-doctoral researcher in the area of mouse molecular genetics and then qualified as a solicitor specialising in intellectual property and commercial law.
Ian Tomlinson, Chairman of the SBC Board, said, 'As representatives of two of our stakeholders and experts in healthcare innovation, we are delighted to welcome Dave and Daniel to the SBC Board. With the Accelerator now occupied by MRC Technology and Tusk Therapeutics, and the Cell and Gene Therapy Catapult's manufacturing centre opening in 2017, these are exciting times at SBC. The insight of our new Stakeholder Directors will be invaluable as we grow further.'
Photographs available on request
For more information, please contact:
Stevenage Bioscience Catalyst
Martino Picardo, CEO +44(0)1438 906906
Emma Palmer Foster, Strategic Communications Consultant
Notes for Editors
About Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst (SBC) opened as the UK's first open innovation biomedical campus in 2012, and combinesa unique blend of infrastructure and virtual networks to drive collaboration. Backed by a novel partnership between Government, GlaxoSmithKline and Wellcome, the remit was, and remains, to catalyse innovation for patient benefit in a phased development. SBC has a strong commitment to companies that focus on high quality science and share its vision, and its development of activity clusters and direct access to the expertise of a major pharmaceutical company are among its unique characteristics. There is start-up and grow-on space for companies, plus a commercially focused management team viewed as a leader in UK incubation. With Phase 1 at capacity, the next phase is in development for the continuation of the collaborative vision. Co-located with GlaxoSmithKline in Stevenage, Stevenage Bioscience Catalyst is located close to both London and Cambridge. For more information, please go to www.stevenagecatalyst.com. Follow us on twitter @SteBioCat
About Stevenage Bioscience Catalyst's stakeholders
Stevenage Bioscience Catalyst's stakeholders are GlaxoSmithKline (www.gsk.com), Wellcome (www.wellcome.ac.uk), the Department for Business, Energy and Industrial Strategy (www.gov.uk/government/organisations/department-for-business-energy-and-industrial-strategy; formerly the Department for Business, Innovation and Skills), and Innovate UK (formerly the Technology Strategy Board; www.innovateuk.org).